

Disclosures

Personal Commercial (3)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|--------------|---------------------------|--------------------|-------------------|
| <i>Self</i> | | | |
| 89bio | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Prevention</i> |
| Amarin | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Prevention</i> |
| Pfizer | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Prevention</i> |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------|--------------------------|--------------------------|-------------------|
| <i>Self</i> | | | |
| VA Merit Award | Research/Research Grants | Significant (>= \$5,000) | <i>Prevention</i> |

Clinical Trial Enroller (3)

| Trial Name | Trial Sponsor | Trial Funding Source |
|------------|----------------------|----------------------|
| PROMINENT | Kowa | |
| HORIZON | Novartis Corporation | |
| SELECT | Novo Nordisk Inc. | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

| Year | Case Title | Represented | Description | Compensation |
|-------------|-------------|---------------------------|--|--------------------------|
| <i>Self</i> | | | | |
| 2020 | Lipitor MDL | Defendant † Pfizer Inc | Class Action Lawsuit alleging that Lipitor caused diabetes in women. | Significant (>= \$5,000) |

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/25/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/25/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 7/25/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 7/25/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members

involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.